The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

AbbVie proved big pharma will pay up for late-stage immunology, and three names keep surfacing on Wall Street's who’s-next ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...

SEC-registered, FINRA-member platform expands capital access for life science innovators SAN DIEGO, CA, UNITED STATES, ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

The acquisition should close in the third quarter and values the biotech at $135.11 per share in cash.

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.